Bigpharma Partnering Agreements

The Bigpharma Partnering Agreements provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.

Understanding the flexibility of a prospective partner's negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 1,200 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of bigpharma's dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers in 2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-6 according to reported deal size.

The main body of the report is provided in chapter 5. Each of the top 50 bigpharma companies is provided with a brief summary followed by a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type - therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.

Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. In addition, the contract document collection can be used offline and is available on CD-Rom.

Key benefits

Bigpharma Partnering Agreements provides the user with the following key benefits:

• Comprehensive access to over 1,200 actual contracts entered into by the leading fifty biopharma companies*
• Insight into the terms included in a partnering agreement, together with real world clause examples
• Understand the key deal terms the company has agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies
• Subject to being published via regulatory requirements of the Securities Exchange Commission.

Report scope

Bigpharma Partnering Agreements is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company's approach to partnering.

Bigpharma Partnering Agreements includes:

• The tools tenable effective and efficient preparation for partnering negotiation with bigpharma
• Detailed partnering activity and interests profiles for the leading fifty bigpharma companies
• Listing of over 1,200 contract documents between bigpharma and partner companies
• The leading M&A and partnering deals by value 2005-6
• Most active M&A and partnering dealmakers 2005-6
• The leading partnering resources

For each company in Bigpharma Partnering Agreements, the available contracts are listed by deal type, including:

• Co-development
• Co-marketing
• Co-promotion
• Collaborative R&D
• Development
• Distribution
• Joint venture
• Licensing
• M&A
• Manufacturing
• Marketing
• Promotion
• Research
• Supply

Each deal title links via Weblink tan online version of the actual contract document, providing easy access teach contract document on demand. In addition, the contract document collection can be used offline and is available on CD-Rom.

The Bigpharma Partnering Agreements provides comprehensive access tavailable contract documents for each of the fifty bigpharma companies. Analyzing actual company agreements allows assessment of the following:

• What is actually granted by the agreement tthe partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Whis responsible for commercialization?
• Whis responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes tbe resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subscontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear tdiffer from partner tpartner or deal type tdeal type?
• Which jurisdiction does the company insist upon for agreement law?